Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59461

1.

Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease.

Sawada H, Oeda T, Umemura A, Tomita S, Kohsaka M, Park K, Yamamoto K, Sugiyama H.

PLoS One. 2015 Jul 28;10(7):e0134118. doi: 10.1371/journal.pone.0134118. eCollection 2015.

PMID:
26218286
2.

Antagonism of quercetin against tremor induced by unilateral striatal lesion of 6-OHDA in rats.

Mu X, Yuan X, Du LD, He GR, Du GH.

J Asian Nat Prod Res. 2015 Jul 28:1-7. [Epub ahead of print]

PMID:
26217978
3.

Oxidative stress and Parkinson's disease.

Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR.

Front Neuroanat. 2015 Jul 8;9:91. doi: 10.3389/fnana.2015.00091. eCollection 2015. Review.

PMID:
26217195
4.

Subthalamic deep brain stimulation reduces pathological information transmission to the thalamus in a rat model of parkinsonism.

Anderson CJ, Sheppard DT, Huynh R, Anderson DN, Polar CA, Dorval AD.

Front Neural Circuits. 2015 Jul 6;9:31. doi: 10.3389/fncir.2015.00031. eCollection 2015.

PMID:
26217192
5.

Closed-loop stimulation of a delayed neural fields model of parkinsonian STN-GPe network: a theoretical and computational study.

Detorakis GI, Chaillet A, Palfi S, Senova S.

Front Neurosci. 2015 Jul 10;9:237. doi: 10.3389/fnins.2015.00237. eCollection 2015.

PMID:
26217171
6.

Dyskinesias and impulse control disorders in Parkinson's disease: from pathogenesis to potential therapeutic approaches.

Jiménez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz Mc MC.

Neurosci Biobehav Rev. 2015 Jul 24. pii: S0149-7634(15)00195-5. doi: 10.1016/j.neubiorev.2015.07.010. [Epub ahead of print] Review.

PMID:
26216865
7.

Periodic hiccup in patients with subthalamic deep brain stimulation for Parkinson's disease.

Jochim A, Castrop F, Gempt J, Haslinger B.

Parkinsonism Relat Disord. 2015 Jul 18. pii: S1353-8020(15)00301-6. doi: 10.1016/j.parkreldis.2015.07.010. [Epub ahead of print] No abstract available.

PMID:
26216075
8.

White matter differences between multiple system atrophy (Parkinsonian type) and Parkinson's disease: a DTI study.

Ji L, Wang Y, Zhu D, Liu W, Shi J.

Neuroscience. 2015 Jul 24. pii: S0306-4522(15)00684-3. doi: 10.1016/j.neuroscience.2015.07.060. [Epub ahead of print]

PMID:
26215920
9.

Causes of Death Associated With Prolonged TV Viewing: NIH-AARP Diet and Health Study.

Keadle SK, Moore SC, Sampson JN, Xiao Q, Albanes D, Matthews CE.

Am J Prev Med. 2015 Jul 24. pii: S0749-3797(15)00265-2. doi: 10.1016/j.amepre.2015.05.023. [Epub ahead of print]

PMID:
26215832
10.

Parkinson disease: Exercise could improve cognition in Parkinson disease.

[No authors listed]

Nat Rev Neurol. 2015 Jul 28. doi: 10.1038/nrneurol.2015.131. [Epub ahead of print] No abstract available.

PMID:
26215623
11.

Parkinson disease: Depression-risk factor or early symptom in Parkinson disease?

Leentjens AF.

Nat Rev Neurol. 2015 Jul 28. doi: 10.1038/nrneurol.2015.126. [Epub ahead of print] No abstract available.

PMID:
26215622
12.

Antimicrobial peptide, Lumbricusin, ameliorates motor dysfunction and dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Kim DH, Lee IH, Nam ST, Hong J, Zhang P, Lu LF, Hwang JS, Park KC, Kim H.

J Microbiol Biotechnol. 2015 Jul 28. doi: 10.4014/jmb.1507.07011. [Epub ahead of print]

PMID:
26215270
13.

Transiently impaired neurogenesis in MPTP mouse model of Parkinson's disease.

He XJ, Nakayama H.

Neurotoxicology. 2015 Jul 25. pii: S0161-813X(15)00114-X. doi: 10.1016/j.neuro.2015.07.007. [Epub ahead of print]

PMID:
26215120
14.

Neonatal chlorpyrifos exposure induces loss of dopaminergic neurons in young adult rats.

Zhang J, Dai H, Deng Y, Tian J, Zhang C, Hu Z, Bing G, Zhao L.

Toxicology. 2015 Jul 24. pii: S0300-483X(15)30019-6. doi: 10.1016/j.tox.2015.07.014. [Epub ahead of print]

PMID:
26215101
15.

Novel LRRK2 mutations in Parkinsonism.

Trinh J, Guella I, McKenzie M, Gustavsson EK, Szu-Tu C, Petersen MS, Rajput A, Rajput AH, McKeown M, Jeon BS, Aasly JO, Bardien S, Farrer MJ.

Parkinsonism Relat Disord. 2015 Jul 18. pii: S1353-8020(15)00302-8. doi: 10.1016/j.parkreldis.2015.07.011. [Epub ahead of print] No abstract available.

PMID:
26213354
16.

Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.

van Laar T, Nyholm D, Nyman R.

Acta Neurol Scand. 2015 Jul 24. doi: 10.1111/ane.12464. [Epub ahead of print]

PMID:
26213103
17.

Reply:Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson´s Disease in the UK and Germany.

Walter E, Odin P.

J Med Econ. 2015 Jul 27:1-8. [Epub ahead of print] No abstract available.

PMID:
26212480
18.

Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality.

Danti S, Toschi N, Diciotti S, Tessa C, Poletti M, Del Dotto P, Lucetti C.

Eur J Neurol. 2015 Jul 24. doi: 10.1111/ene.12785. [Epub ahead of print]

PMID:
26212370
19.

The Use of Transdermal Therapeutic Systems in Psychiatric Care: A Primer on Patches.

Stevens JR, Justin Coffey M, Fojtik M, Kurtz K, Stern TA.

Psychosomatics. 2015 Apr 1. pii: S0033-3182(15)00060-2. doi: 10.1016/j.psym.2015.03.007. [Epub ahead of print] Review.

PMID:
26211981
20.

Purinergic signaling in Parkinson's disease. Relevance for treatment.

Navarro G, Borroto-Escuela DO, Fuxe K, Franco R.

Neuropharmacology. 2015 Jul 23. pii: S0028-3908(15)30031-9. doi: 10.1016/j.neuropharm.2015.07.024. [Epub ahead of print] Review.

PMID:
26211977
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk